Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.
Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback